Abstract
Breast cancer is the commonest type of cancer in European women. About half of the patients develop advanced disease following surgery. The majority of these patients suffer from osteolytic bone metastases at some time during the course of their disease (Elte et al. 1986). Hypercalcemia is a frequent complication in patients with extensive lesions in the skeleton. Osteolytic bone metastases cause severe morbidity and often incapacitate the patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Thesingh CW, Bijvoet OLM (1986) Two modes of action of bisphosphonates on osteolytic resorption of mineralized bone matrix. Bone Mineral 1: 27–39.
Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Bijvoet OLM (1987) Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Mineral 2: 29–42.
Delmas PD, Charbon SA, Chapuy MC, Meunier PJ (1984) Place des diphosphonates dans le thérapeutique de l’ostéolyse et des hypercalcémiees malignes. Rev Rhum Mal Osteoartic 51: 663–666.
Elomaa I, Blomquist C, Grôhn P (1983) Long-term controlled trial with diphosphonate in patients with ostelolytic bone metastases. Lancet 1: 146–149.
Elomaa I, Blomquist C, Porrka L (1985) Diphosphonates for osteolytic metastases. Lancet 1: 1155–1156.
Elte JWF, Bijvoet OLM, Cleton FJ, van Oosterom AT, Sleeboom WP (1986) Osteolytic bone metastasis in breast carcinoma: pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol 22: 493–500.
Fleisch H (1982) Bisphosphonates: mechanism of action and clinical applications. In: Peck WA (ed) Bone mineral research, vol I. Exerpta Medica, Amsterdam, pp 319–357.
Harinck HIJ, Bijvoet OLM, Planting AST, Body JJ, Elte JWF, Sleeboom HP, Wildiers J, Neyt JP (1987 a) Role of bone kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 82: 1133–1142.
Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahlinghaus-Nienhuys PJ (1987 b) Efficacious management with APD in Paget’s disease of bone. Clin Orthop Rel Res 217: 79–98.
Hoekman K, Papapoulos SE, Bijvoet OLM (1985) Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 61: 952–965.
Jung A (1982) Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 72: 221–226.
Lemkes HPJJ, Reitsma PH, Frijlink WB (1978) A new bisphosphonate: dissociation between effects on cells and mineral in rats and a preliminary trial in Paget’s disease. Adv Exp Med Biol 103: 459–569.
Mundy GR, Wilkinson R, Heath DA (1983) Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 74: 421–432.
Siris ES, Hijman GA, Canfield ER (1983) Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 74: 401–406.
Sleeboom HP, Bijvoet OLM, van Oosterom AT, Eleed JH, O’Riddan JLM (1983) Efficacy of intravenous APD on serum calcium, magnesium and creatinine in tumour hypercalcaemia, compared with volume repletion. Lancet 2: 239–243.
van Breukelen FJM, Bijvoet OLM, van Oosterom AT (1979) Inhibition of osteolytic bone lesions by APD. Lancet 1: 803–806.
van Breukelen FJM, Bijvoet OLM, FrijlinkWB, Sleeboom HP, Mulder H, van Oosterom AT (1982) Efficacy of APD in hypercalcaemia: observations on regulation of serum calcium. Calc Tiss Int 34: 321–327.
van Holten-Verzantvoort ATh, Bijvoet OLM, Cleton FJ, Hermans J, Kroon HM, Harinck HIJ, Vermey P, Elte JWF, Neijt JP, Beex LVAM, Blijham G (1987) Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 2: 983–985.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Cleton, F.J., van Holten-Verzantvoort, A.T., Bijvoet, O.L.M. (1989). Effect of Long-Term Bisphosphonate Treatment on Morbidity Due To Bone Metastases in Breast Cancer Patients. In: Brunner, K.W., Fleisch, H., Senn, HJ. (eds) Bisphosphonates and Tumor Osteolysis. Recent Results in Cancer Research, vol 116. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83668-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-83668-8_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83670-1
Online ISBN: 978-3-642-83668-8
eBook Packages: Springer Book Archive